◎ Sugi Atlas

Atlas / Drug / Epacadostat

Epacadostat

drug
On this page

Also known as INCB-024360INCB024360US9320732, 1EPACADOSTAT (INCB024360)

Summary

Epacadostat (CHEMBL3545369) is a phase-3 clinical-stage small molecule (ATC L01XX58) targeting IDO1; indicated across 35 conditions including cutaneous melanoma and neoplasm.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • ATC class: L01XX58
  • Targets: 1 (IDO1)
  • Indications: 35 conditions
  • Clinical trials: 58
  • Chemistry: 438.24 Da · C11H13BrFN7O4S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3545369
NameEpacadostat
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID135564890
ATCL01XX58
Molecular formulaC11H13BrFN7O4S
Molecular weight438.24
InChIKeyFBKMWOJEPMPVTQ-UHFFFAOYSA-N

SMILES: C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F

IUPAC name: N’-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide

Also known as: Epacadostat, INCB-024360, INCB024360, EPACADOSTAT, epacadostat, US9320732, 1, EPACADOSTAT (INCB024360), Epacadostat (INCB024360)

Patent coverage: 2,334 distinct patent families (6,082 SureChEMBL compound mentions), from 8 matched compound structure(s). One matched structure accounts for 5,388 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
IDO1indoleamine 2,3-dioxygenase 1Inhibition7.170%P14902

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Indoleamine 2,3-dioxygenase 1, Tryptophan 2,3-dioxygenase, Indoleamine 2,3-dioxygenase 2, Cytochrome P450 2C9, Cytochrome P450 3A4, Indoleamine 2,3-dioxygenase 2, Indoleamine 2,3-dioxygenase 1.

Bioactivity

ChEMBL activities: 99 potent at pChembl ≥ 5 of 111 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
IDO18.47IC503.4nMCHEMBL_ACT_18369856
IDO18.46IC503.5nMCHEMBL_ACT_23307288
IDO18.3IC505nMCHEMBL_ACT_22447758
IDO18.25IC505.6nMCHEMBL_ACT_19489661
IDO18.15IC507.1nMCHEMBL_ACT_16419281
IDO18.15IC507.1nMCHEMBL_ACT_18369843
IDO18.15IC507nMCHEMBL_ACT_19054236
IDO18.15IC507.1nMCHEMBL_ACT_19054346
IDO18.13IC507.4nMCHEMBL_ACT_17990644
IDO18.13IC507.4nMCHEMBL_ACT_24813966
IDO18.13IC507.4nMCHEMBL_ACT_29199491
IDO18.11IC507.7nMCHEMBL_ACT_19062270
IDO18.1IC507.9nMCHEMBL_ACT_18980385
IDO18.1EC508nMCHEMBL_ACT_20706451
IDO18.06EC508.74nMCHEMBL_ACT_18377568
IDO18.02IC509.63nMCHEMBL_ACT_22467901
IDO18IC5010nMCHEMBL_ACT_18495359
IDO18IC5010nMCHEMBL_ACT_19278801
IDO18IC5010nMCHEMBL_ACT_24518919
IDO18IC5010nMCHEMBL_ACT_24960902
IDO18IC5010nMCHEMBL_ACT_24962866
IDO18IC5010nMCHEMBL_ACT_29199509
IDO17.99IC5010.3nMCHEMBL_ACT_19489631
IDO17.96IC5011nMCHEMBL_ACT_23307300
IDO17.92IC5012nMCHEMBL_ACT_25725785
IDO17.9IC5012.6nMCHEMBL_ACT_19047196
IDO17.9IC5012.5nMCHEMBL_ACT_20679402
IDO17.9IC5012.5nMCHEMBL_ACT_23152538
IDO17.9IC5012.6nMCHEMBL_ACT_24962825
IDO17.89IC5013nMCHEMBL_ACT_18369858
IDO17.89EC5013nMCHEMBL_ACT_20633680
IDO17.82IC5015nMCHEMBL_ACT_18369857
IDO17.82IC5015nMCHEMBL_ACT_26130414
IDO17.8IC5016nMCHEMBL_ACT_19283269
IDO17.73IC5018.6nMCHEMBL_ACT_25447715
IDO17.72IC5019nMCHEMBL_ACT_22920876
IDO17.72IC5019nMCHEMBL_ACT_25477950
IDO17.7IC5020nMCHEMBL_ACT_20669337
IDO17.7IC5020nMCHEMBL_ACT_24911155
IDO17.69IC5020.6nMCHEMBL_ACT_25710881
IDO17.64IC5023nMCHEMBL_ACT_18369855
IDO17.6Kd25.3nMCHEMBL_ACT_29199498
IDO17.58IC5026nMCHEMBL_ACT_22447777
IDO17.52IC5030nMCHEMBL_ACT_23163530
IDO17.5IC5032nMCHEMBL_ACT_28585994
IDO17.48IC5033nMCHEMBL_ACT_28586036
IDO17.45IC5035.76nMCHEMBL_ACT_24518389
IDO17.4IC5040nMCHEMBL_ACT_23163534
IDO17.39IC5040.9nMCHEMBL_ACT_19047162
IDO17.34IC5046nMCHEMBL_ACT_23254732
IDO17.33IC5047nMCHEMBL_ACT_22920864
IDO17.32IC5048nMCHEMBL_ACT_25477925
IDO17.25IC5056nMCHEMBL_ACT_24960946
IDO17.24IC5058nMCHEMBL_ACT_22461013
IDO17.19IC5064.6nMCHEMBL_ACT_18803652
IDO17.18IC5066nMCHEMBL_ACT_20706431
IDO17.17IC5067nMCHEMBL_ACT_16777320
IDO17.17IC5067nMCHEMBL_ACT_19113327
IDO17.16IC5070nMCHEMBL_ACT_18944407
IDO17.16IC5070nMCHEMBL_ACT_19054197
IDO17.16IC5070nMCHEMBL_ACT_25705455
IDO17.14IC5072nMCHEMBL_ACT_15751452
IDO17.14IC5072nMCHEMBL_ACT_16419290
IDO17.14IC5073nMCHEMBL_ACT_17990662
IDO17.14IC5072nMCHEMBL_ACT_18369844
IDO17.14IC5073nMCHEMBL_ACT_18980359
IDO17.14IC5071.8nMCHEMBL_ACT_19054345
IDO17.14IC5072nMCHEMBL_ACT_19113328
IDO17.14IC5072nMCHEMBL_ACT_19278835
IDO17.14IC5071.8nMCHEMBL_ACT_22837778
IDO17.14IC5071.8nMCHEMBL_ACT_22837809
IDO17.14IC5073nMCHEMBL_ACT_24813939
IDO17.14IC5073nMCHEMBL_ACT_24962797
IDO17.14IC5073nMCHEMBL_ACT_25011278
P287767.13IC5074nMCHEMBL_ACT_23307279
P287767.13IC5074nMCHEMBL_ACT_23307551
IDO17.12IC5075nMCHEMBL_ACT_22792011
IDO17.12IC5075.9nMCHEMBL_ACT_25710847
IDO17.11IC5077.8nMCHEMBL_ACT_18707410
IDO17.11IC5077.8nMCHEMBL_ACT_25447698
IDO17.1IC5080nMCHEMBL_ACT_24911102
IDO17.1EC5080nMCHEMBL_ACT_24961013
IDO17.1IC5080nMCHEMBL_ACT_26130472
IDO17.06IC5087.4nMCHEMBL_ACT_22467929
IDO17.05IC5090nMCHEMBL_ACT_20669321
IDO17.04IC5091nMCHEMBL_ACT_24518344
IDO17.03IC5093nMCHEMBL_ACT_24357353
IDO17.01IC5097nMCHEMBL_ACT_20633658
IDO16.9IC50125nMCHEMBL_ACT_17990714
TDO26.62IC50242nMCHEMBL_ACT_19161750
TDO26.58IC50260nMCHEMBL_ACT_19054262
TDO26.58IC50260nMCHEMBL_ACT_19161739
IDO26.2IC50630nMCHEMBL_ACT_25705422
IDO26.15IC50710nMCHEMBL_ACT_19278865
TDO25.67IC502120nMCHEMBL_ACT_23163574
IDO15.46Kd3460nMCHEMBL_ACT_19062313
TDO25.46IC503430nMCHEMBL_ACT_23163554
CYP2C95.11IC507800nMCHEMBL_ACT_23307638
TDO25.11IC507770nMCHEMBL_ACT_24960990

Target pathways

Aggregated over 1 target gene(s): IDO1.

Top Reactome pathways

1 total, by targets touching each:

PathwayTargetsGenes
Tryptophan catabolism1IDO1

Dominant GO biological processes

GO termTargets
positive regulation of T cell tolerance induction1
positive regulation of chronic inflammatory response1
positive regulation of type 2 immune response1
L-tryptophan catabolic process1
inflammatory response1
female pregnancy1
obsolete L-tryptophan catabolic process to L-kynurenine1
quinolinate biosynthetic process1
response to lipopolysaccharide1
negative regulation of interleukin-10 production1
positive regulation of interleukin-12 production1
multicellular organismal response to stress1
kynurenic acid biosynthetic process1
‘de novo’ NAD+ biosynthetic process from L-tryptophan1
swimming behavior1

Indications & clinical

Indications

31 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
cutaneous melanoma3MONDO:0005012EFO:0000389
neoplasm3MONDO:0005070EFO:0000616
renal cell carcinoma3MONDO:0005086EFO:0000681
melanoma3MONDO:0005105EFO:0000756
head and neck cancer3MONDO:0005627EFO:0006859
lung neoplasm3MONDO:0021117MONDO:0008903
myelodysplastic syndrome2MONDO:0018881EFO:0000198
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
sarcoma2MONDO:0005089EFO:0000691
small cell lung carcinoma2MONDO:0008433EFO:0000702
thymic carcinoma2MONDO:0006451EFO:1000576
endometrial carcinoma2MONDO:0002447EFO:1001512
ovarian carcinoma2MONDO:0005140EFO:0001075
hereditary breast ovarian cancer syndrome2MONDO:0003582Orphanet:145
ovarian cancer2MONDO:0008170MONDO:0008170
urothelial carcinoma2MONDO:0040679EFO:0008528
endometrium neoplasm2MONDO:0021251MONDO:0011962
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
paraganglioma2MONDO:0000448EFO:1000453
uveal melanoma2MONDO:0006486EFO:1000616
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
acute myeloid leukemia1MONDO:0018874EFO:0000222
lymphoma1MONDO:0005062EFO:0000574
non-small cell lung carcinoma1MONDO:0005233EFO:0003060
metastatic prostate carcinoma1MONDO:0004956EFO:0000196
glioblastoma1MONDO:0018177EFO:0000519
fallopian tube carcinoma1MONDO:0006206EFO:1000251
rectal cancer1MONDO:0006519EFO:1000657
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
hematopoietic and lymphoid system neoplasm1MONDO:0002334MONDO:0044881

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 58.

Phase distribution

PhaseTrials
PHASE224
PHASE1/PHASE216
PHASE110
PHASE37
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02752074PHASE3COMPLETEDA Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
NCT03260894PHASE3COMPLETEDPembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT03342352PHASE3WITHDRAWNNivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
NCT03348904PHASE3TERMINATEDNivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
NCT03358472PHASE3COMPLETEDPembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
NCT03361865PHASE3COMPLETEDPembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
NCT03374488PHASE3COMPLETEDPembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
NCT03414229PHASE2ACTIVE_NOT_RECRUITINGA Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
NCT03516708PHASE1/PHASE2RECRUITINGEpacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
NCT04463771PHASE2ACTIVE_NOT_RECRUITINGSafety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT01604889PHASE1/PHASE2TERMINATEDA Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
NCT01685255PHASE2TERMINATEDA Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
NCT01822691PHASE2COMPLETEDPhase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
NCT01961115PHASE2COMPLETEDEpacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
NCT02166905PHASE1/PHASE2COMPLETEDDEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT02178722PHASE1/PHASE2COMPLETEDStudy to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
NCT02318277PHASE1/PHASE2COMPLETEDA Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
NCT02327078PHASE1/PHASE2COMPLETEDA Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
NCT02364076PHASE2UNKNOWNPembrolizumab and Epacadostat in Patients With Thymic Carcinoma
NCT02575807PHASE1/PHASE2TERMINATEDSafety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
NCT02785250PHASE1/PHASE2UNKNOWNStudy of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
NCT02959437PHASE1/PHASE2TERMINATEDAzacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
NCT03006302PHASE2COMPLETEDEpacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
NCT03085914PHASE1/PHASE2COMPLETEDA Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
NCT03182894PHASE1/PHASE2WITHDRAWNEpacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
NCT03196232PHASE2COMPLETEDEpacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
NCT03238638PHASE2WITHDRAWNA Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
NCT03277352PHASE1/PHASE2TERMINATEDINCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
NCT03291054PHASE2TERMINATEDEpacadostat and Pembrolizumab in Patients With GIST
NCT03310567PHASE2WITHDRAWNA Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma
NCT03322384PHASE1/PHASE2COMPLETEDUCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
NCT03322540PHASE2COMPLETEDPembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
NCT03322566PHASE2COMPLETEDA Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
NCT03325465PHASE2WITHDRAWNNeoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
NCT03347123PHASE1/PHASE2TERMINATEDA Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
NCT03361228PHASE1/PHASE2TERMINATEDA Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
NCT03402880PHASE2WITHDRAWNALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT03432676PHASE2WITHDRAWNEpacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
NCT03463161PHASE2TERMINATEDEpacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
NCT03493945PHASE1/PHASE2COMPLETEDPhase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
NCT03532295PHASE2COMPLETEDRetifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
NCT03592407PHASE2WITHDRAWNEpacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
NCT03602586PHASE2COMPLETEDTesting Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
NCT03823131PHASE2TERMINATEDOptimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
NCT03832673PHASE2WITHDRAWNPembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study
NCT04231864PHASE2WITHDRAWNDurvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
NCT04586244PHASE2TERMINATEDAn Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
NCT01195311PHASE1COMPLETEDA Dose-escalation Study in Subjects With Advanced Malignancies
NCT02118285PHASE1COMPLETEDIntraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT02298153PHASE1TERMINATEDA Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
NCT02559492PHASE1TERMINATEDItacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
NCT02862457PHASE1COMPLETEDStudy of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
NCT03217669PHASE1UNKNOWNEpacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
NCT03444649PHASE1WITHDRAWNEpacadostat, Idarubicin and Cytarabine (EIC) in AML
NCT03471286PHASE1TERMINATEDA Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
NCT03491579PHASE1WITHDRAWNEpacadostat, Cladribine and Cytarabine (ECC) in AML
NCT03589651PHASE1COMPLETEDINCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
NCT02042430EARLY_PHASE1COMPLETEDEpacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

20 molecules share ≥1 primary target. Top 20 by shared-target count:

MoleculeSourceStatusShared targets
BERBERINEChEMBLPhase 4 (approved)IDO1
BIFONAZOLEChEMBLPhase 4 (approved)IDO1
ECONAZOLEChEMBLPhase 4 (approved)IDO1
ISOCONAZOLEChEMBLPhase 4 (approved)IDO1
KETOCONAZOLEChEMBLPhase 4 (approved)IDO1
MENADIONEChEMBLPhase 4 (approved)IDO1
MICONAZOLEChEMBLPhase 4 (approved)IDO1
MITOMYCINChEMBLPhase 4 (approved)IDO1
OXICONAZOLEChEMBLPhase 4 (approved)IDO1
PHENELZINEChEMBLPhase 4 (approved)IDO1
SERTACONAZOLEChEMBLPhase 4 (approved)IDO1
SULCONAZOLEChEMBLPhase 4 (approved)IDO1
EBSELENChEMBLPhase 3IDO1
LINRODOSTATChEMBLPhase 3IDO1
DICHLOROPHENChEMBLPhase 2IDO1
ENILCONAZOLEChEMBLPhase 2IDO1
INDOXIMODChEMBLPhase 2IDO1
LAPACHONEChEMBLPhase 2IDO1
NAVOXIMODChEMBLPhase 2IDO1
Berberine ChloridePubChemApprovedIDO1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot